2026-10-25
Does not pass
VSee Health does not pass the ethical screen. The binding factor is interest/revenue 6.2%.
NAS100 28,653 −2.55%
S&P 7,626 −1.23%
GOLD $3,926 −2.62%
BTC $76,692 −1.39%
VIX 18.99 +10.41%
latest tape · as of 14:03 UTC
The Screen · Healthcare · Health Information Services
VSee Health Inc
VSEE · NASDAQ · USD · Market cap $1M · 209 employees
VSee Health, Inc.
FAIL · Does not pass the screen2.10 USD
Price as of 12 Oct 2026Daily close, not a live quoteLast reviewed 18 days ago
Screened 2026-10-12 · the tape above runs as of 14:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price2.10 USD at the 12 Oct 2026 close
- Ethical screenDoes not pass
- Last reviewed12 Oct 2026 (18 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 2.10 against the desk's fair-value range, over the last year.
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Price2.10 USD
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markup0.02+10,797.5% to today ✓Distribution gives way to Markup after an 80% slide in 7 weeks
2026-08-16Read Distribution0.10+2,068.3% to today Markup gives way to Distribution after a 32% slide in 6 weeks
2026-07-02Read Markup0.14+1,381.1% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its markup label.
VSee Health Inc holds its Markup at $2.10. Consolidating, no directional conviction, held for 5 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 5 days |
| Price at the screen | $2.10 |
| Valuation | N/A trailing · N/A forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 0.40 |
Five Screens, Shown in Full
Does not pass. Interest/revenue 6.2%
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 14.54% | Below 33% | Interest-bearing debt is just 14.5% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 34.74% | Below 49% | Money owed to the company is 34.7% of assets, under the 49% limit. | Pass |
| Revenue purity | 6.22% | Below 5% | 6.2% of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
VSee Health does not pass the ethical screen. The binding factor is interest/revenue 6.2%.
Read as at 2026-10-29. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
VSee Health clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 15%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
Follow this verdict
Get an email when VSEE's ethical verdict changes
Today VSEE does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
| EPS, trailing | -42.51 |
| Revenue growth | +48.0%growing very fast |
| Profit margin | -62.6%currently unprofitable |
| Return on equity | -1,455.9%not currently earning a positive return on equity |
| FCF yield | -626.34% |
| Debt to equity | 0.27minimal debt: a conservative balance sheet |
| Current ratio | 0.40below 1: short-term bills exceed liquid assets |
| Beta | 0.40barely tracks the market's swings |
| Short interest, float | 0.15% |
| 52-week range | 0.02 - 201.60 |
| Moat | NONE |
| Market cap | $1M |
| Employees | 209 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeVSEE trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-10-23
Markup $2.10
+10,797.5% Entry 7
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10797.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 86%. Our forward projection puts the odds of a 10% gain over the next month near 16%.
2026-10-02
Markup · changed $0.02
+30.4% Entry 6
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 30.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 86%. Our forward projection puts the odds of a 10% gain over the next month near 16%.
2026-09-16
Distribution $0.01
-84.7% Entry 5
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 84.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 86%. Our forward projection puts the odds of a 10% gain over the next month near 16%.
2026-08-16
Distribution · changed $0.10
-31.7% Entry 4
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 31.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 86%. Our forward projection puts the odds of a 10% gain over the next month near 16%.
2026-07-18
Markup $0.14
+0.0% Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 86%. Our forward projection puts the odds of a 10% gain over the next month near 16%.
2026-07-03
Markup $0.14
+0.0% Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02
Markup $0.14
Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- VSee Health Poised for Growth Yahoo Finance · 27 Aug 2026
- VSee Health Signs LOI for Healthcare Platform Acquisition Target With Over $35 Million in Annualized Revenue InvestorsHub · 30 Jul 2026
- VSee Health Signs LOI for Healthcare Platform Acquisition Target With Over $35 Million in Annualized Revenue Yahoo Finance · 30 Jul 2026
- VSee Enters into Letter of Intent to Acquire Vertically Integrated Healthcare Commerce Platform - Acquisition, Valued at $42Million, Would Add over $35Million in Annualized Revenue and More than $7Million in Earnings Yahoo Finance · 30 Jul 2026
- VSEE Vertically Integrated Healthcare Commerce Platform Yahoo Finance · 29 Jul 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
HCTIHealthcare Triangle Inc
MNDRMobile health Network Solutions
ZCMDZhongchao Inc
ACONAclarion Inc
MGRXMangoceuticals Inc
BFRGBullfrog AI Holdings Inc
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $0.18 | -10.8% | · | $892 | -10.8% |
| 2 months | $0.23 | -31.7% | · | $683 | -31.7% |
| 3 months | $0.28 | -43.9% | · | $561 | -43.9% |
| 6 months | $0.54 | -70.9% | · | $291 | -70.9% |
| 1 year | $1.15 | -86.3% | · | $137 | -86.3% |
| 2 years | $15.15 | -99.0% | · | $10 | -99.0% |
| 3 years | $11.44 | -98.6% | · | $14 | -98.6% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever VSEE does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.